24-mCAF was also able to restrain the activity of AKT, AURKB, and two Ser/Thr kinases involved in MYBBP1A modulation, demonstrating the potential of these proteins as therapeutic targets in NSCLC [66]. This evidence concerns the gene AURKB and non-small cell lung carcinoma.